[Federal Register Volume 79, Number 240 (Monday, December 15, 2014)]
[Notices]
[Pages 74092-74093]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-29337]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    James P. Warne, Ph.D., University of California San Francisco: 
Based on an assessment conducted by the University of California San 
Francisco (UCSF), the Respondent's admission, and additional analysis 
conducted by ORI in its oversight review, ORI found that Dr. James P. 
Warne, former Senior Scientist, Diabetes Center, UCSF School of 
Medicine, engaged in research misconduct in research supported by 
National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK), National Institutes of Health (NIH), grants DK080427, 
DK007161, and DK063720.
    ORI found that Respondent engaged in research misconduct by 
falsifying data that were included in the following two (2) 
publications and two (2) grant applications:

     Cell Metabolism 14:791-803, 2011 (hereafter referred to as 
the ``Cell Metabolism paper'')
     Journal of Neuroscience 33(29):11972-85, 2013 (hereafter 
referred to as the ``Journal of Neuroscience paper'')
     R01 DK080427-06A1 submitted to NIDDK, NIH
     R01 AA022665-01A1 submitted to the National Institute on 
Alcohol Abuse and Alcoholism (NIAAA), NIH

ORI found that Respondent falsified data and related text by altering 
the experimental data to support the experimental hypothesis. 
Specifically:
    1. Respondent fabricated graphs purported to represent the results 
of ten (10) different ELISA experiments measuring norephinephrin (NE) 
or leptin levels in wild-type mice, in AGRP knockout mice, or in AGRP 
RNAi mice and controls that had received brain infusions of alpha-MPT, 
a tyrosine hydroxylase inhibitor or vehicle and leptin or AGRP in the 
following figures:


[[Page 74093]]


 Figures 2D/E, 3G, and 7C in the Cell Metabolism paper
 Figures 6B/C/E, Figure 8C, and Figure 9H in the Journal of 
Neuroscience paper; Figures 6B/C/E of the Journal of Neuroscience paper 
also were included as Figures 5A/C/B in grant application DK080427-
06A1, and Figure 8C of the Journal of Neuroscience paper also was 
included as Figure 8C in grant application DK080427-06A1
 Figure 10B in grant application DK080427-06A1

    2. Respondent fabricated graphs purported to represent the results 
of six (6) different quantitative polymerase chain reaction (Q-PCR) 
experiments measuring mRNA levels in mouse liver from wild-type or AGRP 
RNAi mice and controls that had received brain infusions of alpha-MPT, 
a tyrosine hydroxylase inhibitor or vehicle and leptin, AGRP knockout 
mice injected with ethanol, or wild-type mice injected with ethanol and 
caffeine in the following figures:

 Figure 2F in the Cell Metabolism paper
 Figures 5A, 6F, and 9A in the Journal of Neuroscience paper; 
Figure 5A of the Journal of Neuroscience paper also was included as 
Figure 4A in grant application DK080427-06A1, and Figure 6F of the 
Journal of Neuroscience paper also was included as Figure 7A in grant 
application DK080427-06A1
 Figure 3B in grant application AA022665-06A1

Dr. Warne has entered into a Voluntary Settlement Agreement (Agreement) 
and has voluntarily agreed:
    (1) to have his research supervised for a period of three (3) 
years, beginning on November 18, 2014; Respondent agrees that prior to 
the submission of an application for U.S. Public Health Service (PHS) 
support for a research project on which the Respondent's participation 
is proposed and prior to Respondent's participation in any capacity on 
PHS-supported research, Respondent shall ensure that a plan for 
supervision of his duties is submitted to ORI for approval; the 
supervision plan must be designed to ensure the scientific integrity of 
Respondent's research contribution; Respondent agrees that he shall not 
participate in any PHS-supported research until such a supervision plan 
is submitted to and approved by ORI; Respondent agrees to maintain 
responsibility for compliance with the agreed upon supervision plan;
    (2) that for a period of three (3) years, beginning on November 18, 
2014, any institution employing him shall submit, in conjunction with 
each application for PHS funds, or report, manuscript, or abstract 
involving PHS-supported research in which Respondent is involved, a 
certification to ORI that the data provided by Respondent are based on 
actual experiments or are otherwise legitimately derived and that the 
data, procedures, and methodology are accurately reported in the 
application, report, manuscript, or abstract;
    (3) to exclude himself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant for a period of three (3) years, beginning on November 18, 
2014; and
    (4) that as a condition of the Agreement, the senior authors will 
request retraction or correction of the following papers:

 Cell Metabolism 14:791-803, 2011
 Journal of Neuroscience 33(29):11972-85, 2013

FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014-29337 Filed 12-12-14; 8:45 am]
BILLING CODE 4150-31-P